Acquisition Completed Sponsor buyer
Chiesi Group acquisition of KalVista Pharmaceuticals
US$1.9bn equity value
Announced 29 Apr 2026 · NASDAQ: KALV · US$27.00 cash per share · 36% premium
Advisers
KalVista Pharmaceuticals
Target
- Financial adviser
- Legal adviser
- Fairness opinion
- Target
- KalVista Pharmaceuticals
- Acquirer
- Parent (Chiesi Group)
- Sponsor
- Chiesi Group
- Target based in
- United States
- Buyer based in
- Italy
- Completed
- 11 Jun 2026
- Sector
- Pharma
- Tags
- Pharma, Biotech, Rare Disease
In the league tables
- M&A financial advisers, 2026 to date Centerview Partners #5 · Lazard #11 · Jefferies #14
- M&A financial advisers, completed, 2026 to date Centerview Partners #7 · Lazard #14 · Jefferies #22
- M&A legal advisers, 2026 to date Kirkland & Ellis #1 · Ropes & Gray #25 · Fenwick & West #66
- M&A legal advisers, completed, 2026 to date Kirkland & Ellis #3 · Ropes & Gray #27 · Fenwick & West #52
- Fairness opinion providers, 2026 to date Centerview Partners #4
Similar deals
- Neurocrine Biosciences acquisition of Soleno Therapeutics Apr 2026 · US$2.9bn · Biotech
- BioMarin acquisition of Amicus Therapeutics Dec 2025 · US$4.8bn · Biotech
- Vertex Pharmaceuticals acquisition of Crinetics Pharmaceuticals Jul 2026 · US$10bn · Biotech
- Quince Therapeutics acquisition of Orphai Therapeutics May 2026 · Biotech
- Fresenius acquisition of mAbxience Oct 2026 · US$1.9bn · Biotech
Sources
- 2026 Centerview Partners: Financial Advisor to KalVista on its sale to Chiesi centerviewpartners.com
- Apr 2026 Kirkland Advises KalVista on $1.9 Billion Acquisition by Chiesi kirkland.com
- 29 Apr 2026 Target tender offer communication (SC14D9C), KalVista Pharmaceuticals, Inc. sec.gov
- 29 Apr 2026 Press release (EX-99.1, exhibit), Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio sec.gov
- 5 May 2026 Tender offer communication (SC TO-C), KalVista Pharmaceuticals, Inc. sec.gov
- 13 May 2026 Tender offer statement (SC TO-T), KalVista Pharmaceuticals, Inc. sec.gov
- 13 May 2026 Target response to tender offer (SC 14D9), KalVista Pharmaceuticals, Inc. sec.gov
- 11 Jun 2026 Press release (EX-99.1, exhibit), Chiesi Group Completes Acquisition of KalVista Pharmaceuticals sec.gov
- 11 Jun 2026 Lazard: ITALY, UNITED STATES Lazard was the Exclusive Financial Advisor to Chiesi on its Announced Acquisition of KalVista Pharmaceuticals for $1.9 billion lazard.com



